Opinion

Video

Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01

This episode covers current sequencing strategies for NSCLC after targeted therapies and platinum chemotherapy, discusses the COMPEL trial with osimertinib, reviews OS and PFS end points from the TROPION-Lung01 study, examines hypotheses behind differential PFS responses in nonsquamous vs squamous NSCLC, and addresses what constitutes a clinically meaningful, durable response in heavily pretreated patients with advanced NSCLC and actionable genomic alterations.

Video content above is prompted by the following:

  • What are your current sequencing strategies for after getting AGA, after getting approved targeted therapies, and after getting platinum chemotherapy?
  • Please discuss the COMPEL trial results with osimertinib.
  • Tell us about the OS and PFS end points of the TROPION-Lung01 study.
  • What are some prevailing hypotheses that might explain the apparent differential PFS response and positive trend in OS with Dato-DXd among patients with nonsquamous vs squamous NSCLC histology?
  • In your professional opinion, what length of time constitutes a clinically meaningful, durable response among heavily pretreated patients with advanced or metastatic NSCLC and actionable genomic alterations?
Related Videos
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.